VOR completes Phase 3 UPSTREAM MG enrollment, expands telitacicept to ocular MG
VOR says it completed enrollment in its global Phase 3 UPSTREAM MG trial and expanded its telitacicept global franchise into ocular myasthenia gravis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.